Please use this identifier to cite or link to this item: https://covid-19.conacyt.mx/jspui/handle/1000/752
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Wu, D
Yang, X
Acceso Abierto
Atribución-NoComercial-SinDerivadas
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
Journal of Microbiology, Immunology, and Infection / Wei Mian Yu Gan Ran za Zhi
2020
Preimpreso
https://coronavirus.1science.com/item/35f6314cc85c644b485331ed6b4a25c439106027
Inglés
VIRUS RESPIRATORIOS
Appears in Collections:Artículos científicos

Upload archives


File SizeFormat 
101921.pdf266.48 kBAdobe PDFView/Open